APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiple Myeloma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Multiple Myeloma Drugs Market Outlook and Growth Opportunities 2026

20 December 2025191 pages

Choose your research edition.

Industry ResearchMultiple Myeloma Drugs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Myeloma Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Multiple Myeloma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Myeloma Drugs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Myeloma Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Multiple Myeloma Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Multiple Myeloma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multiple Myeloma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multiple Myeloma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Multiple Myeloma Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Multiple Myeloma Drugs market include Takeda Pharmaceutical, Teva, Johnson & Johnson, Novartis, Merck, Amgen, PharmaMar, Daiichi Sankyo and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Multiple Myeloma Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multiple Myeloma Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multiple Myeloma Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Multiple Myeloma Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Multiple Myeloma Drugs Segment by Company

Takeda Pharmaceutical

Teva

Johnson & Johnson

Novartis

Merck

Amgen

PharmaMar

Daiichi Sankyo

Celgene

AB Science

Multiple Myeloma Drugs Segment by Type

Monoclonal Antibodies

Proteasome Inhibitors

Chemotherapy

Immunomodulators

Corticosteroids

Histone Deacetylase (HDAC) Inhibitors

Others

Multiple Myeloma Drugs Segment by Application

Men

Women

Multiple Myeloma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Multiple Myeloma Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Multiple Myeloma Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Multiple Myeloma Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Multiple Myeloma Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Myeloma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Myeloma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Myeloma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multiple Myeloma Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multiple Myeloma Drugs industry.

Chapter 3: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Multiple Myeloma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Multiple Myeloma Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Multiple Myeloma Drugs Industry Trends Table 2. Multiple Myeloma Drugs Industry Drivers Table 3. Multiple Myeloma Drugs Industry Opportunities and Challenges Table 4. Multiple Myeloma Drugs Industry Restraints Table 5. Global Multiple Myeloma Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Multiple Myeloma Drugs Revenue Share by Company (2021-2026) Table 7. Global Multiple Myeloma Drugs Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Multiple Myeloma Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Multiple Myeloma Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Multiple Myeloma Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Multiple Myeloma Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Multiple Myeloma Drugs Company, Product Type & Application Table 13. Global Multiple Myeloma Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Multiple Myeloma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Monoclonal Antibodies Table 18. Significant Companies of Proteasome Inhibitors Table 19. Significant Companies of Chemotherapy Table 20. Significant Companies of Immunomodulators Table 21. Significant Companies of Corticosteroids Table 22. Significant Companies of Histone Deacetylase (HDAC) Inhibitors Table 23. Significant Companies of Others Table 24. Global Multiple Myeloma Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Multiple Myeloma Drugs Sales Volume by Type (2021-2026) & (W Units) Table 26. Global Multiple Myeloma Drugs Sales Volume by Type (2027-2032) & (W Units) Table 27. Global Multiple Myeloma Drugs Sales Volume Share by Type (2021-2026) Table 28. Global Multiple Myeloma Drugs Sales Volume Share by Type (2027-2032) Table 29. Global Multiple Myeloma Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Multiple Myeloma Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Multiple Myeloma Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Multiple Myeloma Drugs Sales Value Share by Type (2021-2026) Table 33. Global Multiple Myeloma Drugs Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Men Table 35. Significant Companies of Women Table 36. Global Multiple Myeloma Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global Multiple Myeloma Drugs Sales Volume by Application (2021-2026) & (W Units) Table 38. Global Multiple Myeloma Drugs Sales Volume by Application (2027-2032) & (W Units) Table 39. Global Multiple Myeloma Drugs Sales Volume Share by Application (2021-2026) Table 40. Global Multiple Myeloma Drugs Sales Volume Share by Application (2027-2032) Table 41. Global Multiple Myeloma Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Multiple Myeloma Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Multiple Myeloma Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Multiple Myeloma Drugs Sales Value Share by Application (2021-2026) Table 45. Global Multiple Myeloma Drugs Sales Value Share by Application (2027-2032) Table 46. Global Multiple Myeloma Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 47. Global Multiple Myeloma Drugs Sales by Region (2021-2026) & (W Units) Table 48. Global Multiple Myeloma Drugs Sales Market Share by Region (2021-2026) Table 49. Global Multiple Myeloma Drugs Sales by Region (2027-2032) & (W Units) Table 50. Global Multiple Myeloma Drugs Sales Market Share by Region (2027-2032) Table 51. Global Multiple Myeloma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Multiple Myeloma Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Multiple Myeloma Drugs Sales Value Share by Region (2021-2026) Table 54. Global Multiple Myeloma Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Multiple Myeloma Drugs Sales Value Share by Region (2027-2032) Table 56. Global Multiple Myeloma Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Multiple Myeloma Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Multiple Myeloma Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. Global Multiple Myeloma Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Multiple Myeloma Drugs Sales by Country (2021-2026) & (W Units) Table 61. Global Multiple Myeloma Drugs Sales Market Share by Country (2021-2026) Table 62. Global Multiple Myeloma Drugs Sales by Country (2027-2032) & (W Units) Table 63. Global Multiple Myeloma Drugs Sales Market Share by Country (2027-2032) Table 64. Global Multiple Myeloma Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Multiple Myeloma Drugs Sales Value Market Share by Country (2021-2026) Table 66. Global Multiple Myeloma Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Multiple Myeloma Drugs Sales Value Market Share by Country (2027-2032) Table 68. Takeda Pharmaceutical Company Information Table 69. Takeda Pharmaceutical Business Overview Table 70. Takeda Pharmaceutical Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio Table 72. Takeda Pharmaceutical Recent Development Table 73. Teva Company Information Table 74. Teva Business Overview Table 75. Teva Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Teva Multiple Myeloma Drugs Product Portfolio Table 77. Teva Recent Development Table 78. Johnson & Johnson Company Information Table 79. Johnson & Johnson Business Overview Table 80. Johnson & Johnson Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Johnson & Johnson Multiple Myeloma Drugs Product Portfolio Table 82. Johnson & Johnson Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Novartis Multiple Myeloma Drugs Product Portfolio Table 87. Novartis Recent Development Table 88. Merck Company Information Table 89. Merck Business Overview Table 90. Merck Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Merck Multiple Myeloma Drugs Product Portfolio Table 92. Merck Recent Development Table 93. Amgen Company Information Table 94. Amgen Business Overview Table 95. Amgen Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Amgen Multiple Myeloma Drugs Product Portfolio Table 97. Amgen Recent Development Table 98. PharmaMar Company Information Table 99. PharmaMar Business Overview Table 100. PharmaMar Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. PharmaMar Multiple Myeloma Drugs Product Portfolio Table 102. PharmaMar Recent Development Table 103. Daiichi Sankyo Company Information Table 104. Daiichi Sankyo Business Overview Table 105. Daiichi Sankyo Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio Table 107. Daiichi Sankyo Recent Development Table 108. Celgene Company Information Table 109. Celgene Business Overview Table 110. Celgene Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Celgene Multiple Myeloma Drugs Product Portfolio Table 112. Celgene Recent Development Table 113. AB Science Company Information Table 114. AB Science Business Overview Table 115. AB Science Multiple Myeloma Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. AB Science Multiple Myeloma Drugs Product Portfolio Table 117. AB Science Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Multiple Myeloma Drugs Distributors List Table 121. Multiple Myeloma Drugs Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Multiple Myeloma Drugs Product Image Figure 2. Global Multiple Myeloma Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Myeloma Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Multiple Myeloma Drugs Sales (2021-2032) & (W Units) Figure 5. Global Multiple Myeloma Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Multiple Myeloma Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Monoclonal Antibodies Image Figure 10. Proteasome Inhibitors Image Figure 11. Chemotherapy Image Figure 12. Immunomodulators Image Figure 13. Corticosteroids Image Figure 14. Histone Deacetylase (HDAC) Inhibitors Image Figure 15. Others Image Figure 16. Global Multiple Myeloma Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Multiple Myeloma Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Multiple Myeloma Drugs Sales Volume Share by Type (2021-2032) Figure 19. Global Multiple Myeloma Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Multiple Myeloma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Multiple Myeloma Drugs Sales Value Share by Type (2021-2032) Figure 22. Men Image Figure 23. Women Image Figure 24. Global Multiple Myeloma Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Multiple Myeloma Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Multiple Myeloma Drugs Sales Volume Share by Application (2021-2032) Figure 27. Global Multiple Myeloma Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Multiple Myeloma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Multiple Myeloma Drugs Sales Value Share by Application (2021-2032) Figure 30. Global Multiple Myeloma Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 31. Global Multiple Myeloma Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Multiple Myeloma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Multiple Myeloma Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Multiple Myeloma Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. North America Multiple Myeloma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Multiple Myeloma Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Multiple Myeloma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Multiple Myeloma Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Multiple Myeloma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Multiple Myeloma Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. South America Multiple Myeloma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Multiple Myeloma Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Multiple Myeloma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Multiple Myeloma Drugs Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Multiple Myeloma Drugs Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Proteasome Inhibitors
  • Chemotherapy
  • Immunomodulators
  • Corticosteroids
  • Histone Deacetylase (HDAC) Inhibitors
  • Others
Applications
  • Men
  • Women
Companies covered
  • Takeda Pharmaceutical
  • Teva
  • Johnson & Johnson
  • Novartis
  • Merck
  • Amgen
  • PharmaMar
  • Daiichi Sankyo
  • Celgene
  • AB Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Multiple Myeloma Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Multiple Myeloma Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Multiple Myeloma Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Multiple Myeloma Drugs Market Dynamics
  1. 2.1 Multiple Myeloma Drugs Industry Trends
  2. 2.2 Multiple Myeloma Drugs Industry Drivers
  3. 2.3 Multiple Myeloma Drugs Industry Opportunities and Challenges
  4. 2.4 Multiple Myeloma Drugs Industry Restraints
3 Multiple Myeloma Drugs Market by Company
  1. 3.1 Global Multiple Myeloma Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Multiple Myeloma Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Multiple Myeloma Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Multiple Myeloma Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Multiple Myeloma Drugs Company Ranking (2024-2026)
  6. 3.6 Global Multiple Myeloma Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Multiple Myeloma Drugs Company Product Type and Application
  8. 3.8 Global Multiple Myeloma Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Multiple Myeloma Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Multiple Myeloma Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Multiple Myeloma Drugs Market by Type
  1. 4.1 Multiple Myeloma Drugs Type Introduction
  2. 4.1.1 Monoclonal Antibodies
  3. 4.1.2 Proteasome Inhibitors
  4. 4.1.3 Chemotherapy
  5. 4.1.4 Immunomodulators
  6. 4.1.5 Corticosteroids
  7. 4.1.6 Histone Deacetylase (HDAC) Inhibitors
  8. 4.1.7 Others
  9. 4.2 Global Multiple Myeloma Drugs Sales Volume by Type
  10. 4.2.1 Global Multiple Myeloma Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Multiple Myeloma Drugs Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Multiple Myeloma Drugs Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Multiple Myeloma Drugs Sales Value by Type
  14. 4.3.1 Global Multiple Myeloma Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Multiple Myeloma Drugs Sales Value by Type (2021-2032)
  16. 4.3.3 Global Multiple Myeloma Drugs Sales Value Share by Type (2021-2032)
5 Multiple Myeloma Drugs Market by Application
  1. 5.1 Multiple Myeloma Drugs Application Introduction
  2. 5.1.1 Men
  3. 5.1.2 Women
  4. 5.2 Global Multiple Myeloma Drugs Sales Volume by Application
  5. 5.2.1 Global Multiple Myeloma Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Multiple Myeloma Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Multiple Myeloma Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Multiple Myeloma Drugs Sales Value by Application
  9. 5.3.1 Global Multiple Myeloma Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Multiple Myeloma Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Multiple Myeloma Drugs Sales Value Share by Application (2021-2032)
6 Multiple Myeloma Drugs Regional Sales and Value Analysis
  1. 6.1 Global Multiple Myeloma Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multiple Myeloma Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Multiple Myeloma Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Multiple Myeloma Drugs Sales by Region (2027-2032)
  5. 6.3 Global Multiple Myeloma Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Multiple Myeloma Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Multiple Myeloma Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Multiple Myeloma Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Multiple Myeloma Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Multiple Myeloma Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Multiple Myeloma Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Multiple Myeloma Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Multiple Myeloma Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Multiple Myeloma Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Multiple Myeloma Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Multiple Myeloma Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Multiple Myeloma Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Multiple Myeloma Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Multiple Myeloma Drugs Sales Value Share by Country, 2025 VS 2032
7 Multiple Myeloma Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Multiple Myeloma Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Multiple Myeloma Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Multiple Myeloma Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Multiple Myeloma Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Multiple Myeloma Drugs Sales by Country (2027-2032)
  6. 7.4 Global Multiple Myeloma Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Multiple Myeloma Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Multiple Myeloma Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Multiple Myeloma Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Multiple Myeloma Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Multiple Myeloma Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical
  2. 8.1.1 Takeda Pharmaceutical Company Information
  3. 8.1.2 Takeda Pharmaceutical Business Overview
  4. 8.1.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Multiple Myeloma Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Multiple Myeloma Drugs Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Multiple Myeloma Drugs Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Multiple Myeloma Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Multiple Myeloma Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Multiple Myeloma Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Multiple Myeloma Drugs Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Amgen
  32. 8.6.1 Amgen Company Information
  33. 8.6.2 Amgen Business Overview
  34. 8.6.3 Amgen Multiple Myeloma Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Amgen Multiple Myeloma Drugs Product Portfolio
  36. 8.6.5 Amgen Recent Developments
  37. 8.7 PharmaMar
  38. 8.7.1 PharmaMar Company Information
  39. 8.7.2 PharmaMar Business Overview
  40. 8.7.3 PharmaMar Multiple Myeloma Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 PharmaMar Multiple Myeloma Drugs Product Portfolio
  42. 8.7.5 PharmaMar Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 Celgene
  50. 8.9.1 Celgene Company Information
  51. 8.9.2 Celgene Business Overview
  52. 8.9.3 Celgene Multiple Myeloma Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Celgene Multiple Myeloma Drugs Product Portfolio
  54. 8.9.5 Celgene Recent Developments
  55. 8.10 AB Science
  56. 8.10.1 AB Science Company Information
  57. 8.10.2 AB Science Business Overview
  58. 8.10.3 AB Science Multiple Myeloma Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AB Science Multiple Myeloma Drugs Product Portfolio
  60. 8.10.5 AB Science Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Multiple Myeloma Drugs Value Chain Analysis
  2. 9.1.1 Multiple Myeloma Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Multiple Myeloma Drugs Sales Mode & Process
  6. 9.2 Multiple Myeloma Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Multiple Myeloma Drugs Distributors
  9. 9.2.3 Multiple Myeloma Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst